Likewise, the FDA and EMA approved Tofersen, an antisense medication for SOD1-ALS based on the reduction of plasma NfL and CSF SOD-1 levels [170, 171]. The gene discussed is NEFL; the disease is amyotrophic lateral sclerosis.